Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis

JAMA Neurol. 2021 May 1;78(5):617-619. doi: 10.1001/jamaneurol.2021.0477.

Sophie N M Binks^{1

2}, Michele Veldsman³, Ava Easton^{4

5}, M Isabel Leite^{1

2}, David Okai⁶, Masud Husain^{3

7}, Sarosh R Irani^{1

2}

¹ Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, England.
² Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, England.
³ Department of Experimental Psychology, University of Oxford, Oxford, England.
⁴ The Encephalitis Society, Malton, North Yorkshire, England.
⁵ Honorary Fellow, Depatment of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, England.
⁶ Department of Neuropsychiatry, Maudsley Outpatients, Denmark Hill, Maudsley Hospital, London, England.
⁷ Nuffield Department of Clinical Neurosciences, Oxford, England.

Abstract

This study evaluates residual fatigue and cognitive defects in patients after leucine-rich glioma-inactivated 1 antibody encephalitis.